Joint Patent Application Filed for lncRNA-Targeting Drugs
Filed with TSE · · 3 pages · English
In the deck
Earlier from Veritas In Silico
- Personnel Changes in Executive Officer
- TABLE-Veritas In Silico -2025 parent results
- TABLE-Veritas In Silico - 9-MTH parent results
- TABLE-Veritas In Silico -2025 parent forecast
Later from Veritas In Silico
- Non-consolidated Financial Results for the Six Months Ended June 30, 2026 [Under Japanese GAAP]
- Notice Concerning Achievement of Research Milestone under Joint Drug Discovery with Toray Industries, Inc.
- Notice of Completion of Payment for #5 and #6 to #9 Share Acquisition Rights by Third-Party Allotment
- Syntara and Veritas In Silico sign MoU to Accelerate Joint Discovery Research for mRNA-Targeted Compounds
- Monthly Status of Exercise of #5 (with Exercise Price Adjustment Clause) and #6 to #9 Share Acquisition Rights(with Target Issue and Adjustment Optio
Follow Veritas In Silico into a list and get an email when it puts out news.
Follow Veritas In Silico